Thermo Fisher reported first-quarter revenue of $12.21 billion, up 7% year-over-year, driven by broad-based strength in life sciences solutions and analytical instrumentation. Adjusted earnings per share of $6.57 represented an 8% increase versus the prior year, reflecting operational leverage on higher volumes and disciplined expense management. Core consumables growth accelerated to low double digits, underscoring resilient demand across biopharma and academic markets.

Management reiterated full-year 2026 revenue guidance of $46.3 billion to $47.2 billion, implying growth of 4–6%, with organic growth expected at approximately 4%. Adjusted EPS is projected in the range of $24.22 to $24.80, up 6–8%, supported by ongoing productivity programs and continued mix shift toward higher-margin services. The company plans incremental investments in digital capabilities and new product launches, which should sustain mid-teens operating margins despite inflationary pressures.

Thermo Fisher’s pending $8.875 billion acquisition of Clario is anticipated to contribute an incremental $0.20 to $0.25 to 2026 EPS, driven by cross-selling opportunities in clinical trial solutions and cost synergies in back-office functions. Management expects the deal to be accretive in year one, with a targeted run-rate of $150 million in synergies by 2027. This transaction reinforces the company’s leadership in the high-growth clinical research market and further diversifies its service portfolio.

Despite the recent pullback in shares, Thermo Fisher’s combination of durable end-market exposure, strong free cash flow generation, and track record of margin expansion supports a favorable risk/reward profile. We reaffirm our Strong Buy rating, citing the company’s ability to deliver consistent organic growth, accretive M&A, and continuous productivity improvements. Investors should view the current valuation as an attractive entry point for long-term exposure to global life sciences enablement.